Biosimilar Path Expected to Be Under Construction for Years
By Mari Serebrov
Friday, February 8, 1991
WASHINGTON The Congressional Research Service (CRS) has a few words for those hoping to use the new biosimilar pathway as a shortcut to cash in quickly on the high price of biologics. Be patient. And watch out. This new road could be under construction for a long time.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.